Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India
Illumina (NASDAQ: ILMN) has announced a $1 million donation to enhance SARS-CoV-2 sequencing at Kasturba Hospital in Greater Mumbai, aiding genomic surveillance across India. This contribution includes two NextSeq™ 2000 NGS platforms, reagents, and four years of service support. CEO Francis deSouza emphasized the importance of democratizing access to sequencing technology in regions burdened by infectious diseases. The initiative aims to support COVID-19 control efforts through advanced genomic capabilities.
- Donation of $1 million in sequencing capabilities.
- Includes advanced NextSeq™ 2000 NGS platforms and bioinformatics support.
- Supports genomic surveillance efforts to track SARS-CoV-2 variants in India.
- None.
SAN DIEGO, Aug. 3, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has donated
"Illumina believes in democratization of access to sequencing and we are committed to helping the regions of the world that carry most of the infectious disease burden to build genomics capabilities," said Francis deSouza, Chief Executive Officer of Illumina. "This donation will help to make NGS technology and expertise accessible in Mumbai, supporting the region and contributing to genomic surveillance in India more broadly."
"We are grateful for Illumina's support in the pandemic fight," said Dr. Jayanthi Shastri, Laboratory Director from the Molecular Diagnostic Reference Laboratory at Kasturba Hospital.
The donation includes two of Illumina's newest next-generation sequencing (NGS) platforms, the NextSeq™ 2000, reagents, a rapid bioinformatics analysis platform (DRAGEN) and four years of service support for the sequencing installations. It is part of Illumina's broader philanthropic program to provide access to NGS technology throughout the world to drive a global response that will be effective in supporting SARS-CoV-2 control efforts.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Source: Illumina, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-donates-1-million-in-sequencing-capabilities-to-mumbai-to-support-sequencing-based-covid-19-surveillance-in-india-301346403.html
SOURCE Illumina, Inc.
